Core Viewpoint - The announcement by Keqian Bio regarding the approval of its inactivated vaccine for porcine Seneca virus disease (HB16 strain) as a new veterinary drug by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] Group 1 - Keqian Bio has received approval for its inactivated vaccine for porcine Seneca virus disease, which is a significant development for the company [1] - The approval was granted in accordance with the Veterinary Drug Management Regulations and the Veterinary Drug Registration Measures [1] - The company has been issued a New Veterinary Drug Registration Certificate following the review by the relevant authorities [1]

Core Viewpoint - The company, Keqian Bio (688526.SH), has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Porcine Seneca Valley Virus (HB16 strain), marking a significant advancement in veterinary medicine [1] Group 1 - The vaccine is specifically designed for the prevention of Porcine Seneca Valley Virus disease [1] - The immunization period begins 21 days after the second vaccination and lasts for 6 months [1] - The approval is in accordance with the "Veterinary Drug Management Regulations" and "Veterinary Drug Registration Measures" [1]

Core Viewpoint - The company, Keqian Bio (688526), has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Porcine Seneca Valley Virus (HB16 strain) as a new veterinary drug [1] Group 1 - The approval is in accordance with the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures" [1] - The company has been issued a "New Veterinary Drug Registration Certificate" for the vaccine [1]